Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × vistusertib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 DLBCL 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1

Interventions

Dexamethasone 46 Cyclophosphamide 28 Lenalidomide 27 pomalidomide 24 Rituximab 23 venetoclax 22 fludarabine 21 Bortezomib 20 Paclitaxel 18 Gemcitabine 18 carfilzomib 16 Carboplatin 15 pembrolizumab 14 Cisplatin 14 daratumumab 13 Docetaxel 12 Calcium Dobesilate 12 Cytarabine 11 Azacitidine 11 obinutuzumab 10 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 ibrutinib 9 durvalumab 8 blinatumomab 8 Injections 8 Cetuximab 8 zanubrutinib 7 selinexor 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡